Arrowhead Pharmaceuticals (ARWR) Non-Current Debt (2011 - 2026)

Arrowhead Pharmaceuticals (ARWR) has 10 years of Non-Current Debt data on file, last reported at $159.6 million in Q1 2026.

• Quarterly Non-Current Debt fell 23.59% year-over-year to $159.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $159.6 million (down 23.59% YoY) and the FY2025 annual result came in at $214.9 million, down 45.35% from the prior year.
• Non-Current Debt fell to $159.6 million in Q1 2026, from $163.1 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $407.8 million in Q4 2024 to a low of $159.6 million in Q1 2026.
• A 3-year average of $249.7 million and a median of $208.9 million in 2025 frame the typical range for Non-Current Debt.
• Annual changes were most pronounced in 2025 — Non-Current Debt sank 60.0% — and 2026, when it fell 23.59%.
• Tracing ARWR's Non-Current Debt over 3 years: stood at $407.8 million in 2024, then slumped by 60.0% to $163.1 million in 2025, then dropped by 2.13% to $159.6 million in 2026.
• The last three Non-Current Debt figures came in at $159.6 million (Q1 2026), $163.1 million (Q4 2025), and $214.9 million (Q3 2025), per Business Quant data.